Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Valeant Pharmaceuticals’ (VRX - Snapshot Report) second quarter 2013 cash earnings per share of $1.34 (excluding special items and non-cash expenses) easily beat the Zacks Consensus Estimate of $1.28 and were up from the year-ago earnings of 0.87 per share.

Revenues for the quarter were $1.1 billion, up 34% from the year-ago period. The year-over-year improvement in revenues was primarily attributable to higher product sales. Revenues were in-line with the Zacks Consensus Estimate.

Quarterly Highlights

Product sales at Valeant amounted to $1.06 billion during the second quarter of 2013, up 43% year over year.

Strong sales in the U.S. Promoted (previously U.S. Dermatology) and Emerging Markets segments contributed to the increase.

Total sales from developed markets jumped 37% year over year to $792 million fuelled by a 90% jump in U.S. Promoted sales to $487 million.

The aesthetics franchise, OraPharma, skin care, and topical acne portfolio drove growth along with the strong performances of Dysport and CeraVe.

Sales from emerging markets grew 26% year over year driven by continued strong growth in Poland, Russia, Brazil, Mexico, South East Asia and South Africa.

Research & development (R&D) expenses climbed 38.1% to $24.5 million.

Selling, general & administrative (SG&A) expenses for the second quarter of 2013 increased 38.8% to $257.4 million due to the integration of Medicis operations.

We note that Valeant recently completed the acquisition of Bausch + Lomb Holdings Incorporated for $8.7 billion. The deal was first announced in May 2013.

Valeant now expects synergies more than the earlier estimate of $800 million from this acquisition. Of the total projected synergies, $500 million is expected in 2013.

2013 Guidance Upped

Valeant upped its guidance for 2013 to include the Bausch+Lomb acquisiton. Valeant now expects revenues between $5.8 billion and $6.2 billion, up from the previous projection of $4.4 billion – $4.8 billion.

Earnings per share on a cash basis are now projected around $6.00 – $6.20, up from the earlier projection of $5.55 –$5.85.

The Zacks Consensus Estimate for 2013 hints at earnings of $5.82 per share on revenues of $5.2 billion.

EPS for the third and fourth quarters of 2013 are projected at $1.33 to $1.43 and $2.03 to $2.13, respectively.

We are encouraged by the second -quarter results, which beat our expectations. We believe the acquisition of Bausch + Lomb will significantly strengthen Valeant’s ophthalmology business given the former’s leading portfolio of eye health products.

The acquisition should also enable Valeant to penetrate into the growing eye health market fueled by an aging patient population, an increased rate of diabetes, and increasing demand from the emerging markets.

We note that Valeant has been active on the acquisition front lately, thereby using its cash reserves. We are also impressed by the company’s integration efforts and increase in expected synergies.

Valeant currently carries a Zacks Rank #3 (Hold). Right now, Jazz Pharmaceuticals (JAZZ - Analyst Report), Shire (SHPG - Analyst Report) and Ironwood Pharmaceuticals (IRWD - Analyst Report) look attractive with a Zacks Rank #2 (Buy).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%